Zacks Investment Research
08 May 2026, 14:56 UTC · 20w ago
Verdict
Headline leans bullish. We score QTTB +0.80 across two claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
2 claims · scored −1 bearish … +1 bullish
Analysts have a positive trend in earnings estimate revisions for Q32 Bio (QTTB), suggesting the company will report better earnings than previously estimated.
More positive than 79% of claims this week
The mean Wall Street price target for QTTB is $14.33, representing a potential 163.4% upside from its recent close of $5.44.
So whatWhile price targets can be optimistic, a significant gap between current price and consensus suggests strong analyst conviction.
Continue reading
5 related stories
More positive than 88% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 53% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company has seen recent price gains and has a mean analyst price target indicating significant upside potential.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
2h ago
+61.2%
Price agrees with the score
$8.77 vs $5.44 close before publication (May 7) · not market-adjusted
QTTB chart →
